<DOC>
	<DOCNO>NCT01023776</DOCNO>
	<brief_summary>The purpose study determine amount live virus recover nose people vaccinate licensed live vaccine H1N1 , describe immune response vaccination .</brief_summary>
	<brief_title>Infectivity , Replication &amp; Immunogenicity Live nH1N1 Vaccine</brief_title>
	<detailed_description>By look immune response vaccine , hope understand factor determine immune response detail shed pattern live novel H1N1 vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 1832 year , inclusive No history Novel H1N1 virus vaccine Female able bear child pregnant agree practice effective birth control Female negative pregnancy test Good Health Ability understand comply protocol Provided Informed Consent Previous history vaccination novel H1N1 laboratory document H1N1 infection History egg allergy allergic component vaccine A woman pregnant breastfeed intend get pregnant study period enrollment 30 day follow vaccination Subject immunosuppressed result underlie illness treatment immunosuppressive cytotoxic drug use chemotherapy radiation therapy precede 36 month Subject active neoplastic disease ( exclude nonmelanoma skin cancer prostate cancer stable absence therapy ) history hematological malignancy . `` active defined treatment within past 5 year Long term ( great 2 week ) use oral parental steroid , high dose inhale steroid ( &gt; 800 mcg/day beclomethasone dipropionate equivalent ) within precede 6 month ( nasal topical steroid allow ) Received immunoglobulin another blood product within 3 month prior enrollment study Subject receive inactivated vaccine within 2 week live vaccine within 4 week prior enrollment study plan receive another vaccine within next 28 day ( 56 day vaccine naive recipient ) Subject acute chronic medical condition , opinion investigator , would render vaccination unsafe would interfere evaluation response . Those condition include chronic condition recognize risk factor influenza complication contraindicate live vaccination , include chronic cardiac ( exclusive hypertension ) pulmonary condition ( include asthma ) , diabetes mellitus , renal impairment Subject acute illness oral temperature great 99.9 degree F ( 37.7 C ) within 3 day prior enrollment vaccination . Subject acute illness treat , symptom resolve eligible enroll long treatment complete symptom resolve &gt; 3 dyas prior enrollment . Subject currently participate plan participate study involve experimental agent ( vaccine , drug , biologic , device , blood product , medication ) receive experimental agent within 1 month prior enrollment study , intend donate blood period . Subject condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol Subject history alcohol drug abuse 5 year prior enrollment . Subject know human immunodeficiency virus , hepatitis B , hepatitis C infection . Subject previous history GuillainBarre syndrome within 6 week receipt influenza vaccine Subject condition principal investigator ( PI ) believe may interfere successful completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>32 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Swine Flu</keyword>
	<keyword>H1N1</keyword>
</DOC>